GlassScriptPhysician profile
Stefan Cadag
NPI 1841408721
$4,172.59
in general payments reported to CMS, 2019-2025
22 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.03 · 2020: $255 · 2021: $139 · 2022: $392 · 2023: $870 · 2024: $1,426 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,334.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $912.83 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Abbott Laboratories | $651.97 | 2020-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $489.65 | 2022-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $452.16 | 2020-2024 | Korlym |
| Novo Nordisk INC | $355.99 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $258.34 | 2022-2025 | Evenity, Prolia, Tepezza |
| Tandem Diabetes Care, INC. | $237.75 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $213.83 | 2023-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.63 | 2023-2025 | Jardiance, Tradjenta |
| Beta Bionics, INC. | $94.03 | 2024 | Ilet Bionic Pancreas |
| Novartis Pharmaceuticals Corporation | $50.63 | 2022-2023 | |
| Glaxosmithkline, LLC. | $41.03 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.73 | 2024 | |
| Idorsia Pharmaceuticals US INC | $34.55 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $33.82 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $25.57 | 2022-2023 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $24.13 | 2024 | Recorlev |
| Janssen Biotech, INC. | $23.88 | 2025 | Tremfya |
| Inspire Medical Systems, INC. | $22.42 | 2024 | Inspire |
| Medtronic, INC. | $18.51 | 2025 | Minimed 780g |
| Janssen Pharmaceuticals, INC | $13.38 | 2023 | Xarelto |
| Acerus Pharmaceuticals Corporation | $12.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefan Cadag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.